Product Description
Similar to acetaminophen (Tylenol®), SRP-001 is an AM404 agonist that targets the endocannabinoid (CB1) pain receptors in the brain. In multiple, validated non-clinical studies, SRP-001 demonstrated consistent, superior analgesic activity than that of acetaminophen. Importantly, however, SRP-001 also avoids liver injury commonly associated with acetaminophen overuse, even at high levels of SRP-001. Specifically, the two mechanisms by which SRP-001 avoids liver toxicity (no production of the toxic metabolite NAPQI and the preservation of hepatic tight junctions) were recently elucidated in a publication in The European Journal of Medicinal Chemistry. The Company believes that the combination of SRP-001's enhanced analgesic activity and its reduced toxicity will result in a superior therapeutic index than that of acetaminophen. (Sourced from: https://www.benzinga.com/pressreleases/22/10/n29133470/south-rampart-pharma-issued-composition-of-matter-patent-for-novel-non-toxic-treatment-for-pain)
Mechanisms of Action: ApAP Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: Fast Track - Acute Pain|Pain Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: South Rampart Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|